Edit: in response to d3outguncomThe 110 formulation was for...

Edit: in response to d3outguncom

The 110 formulation was for central line IV treatment, which was required to get trials underway and has been very beneficial.

Now there's a better formulation available (220) the 110 is being wound up. Think of it as the Xbox 360 replacing the Xbox, it's taking all of the existing technology and building on it to offer a much better product. So is the 110 data wasted? Absolutely not, it's been invaluable in prior years and has now been superseded.

To answer the other two points in one response it appears pursuing the 220 pathway is the quickest way to get to where we need to be in terms of a buyout. Pursuing other 'value add' items is great, and may add some extra buyout capacity, but if it takes longer to achieve and means we've got too many spinning plates to focus on at once then we're at risk of needing a cap raise to keep everything working.

They're equipping the key trials for the best chances of success rather than spreading the resources around for everything that tickles their fancy.